Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - film coated tablets - eletriptan hydrobromide 24.242 mg - eletriptan - acute treatment of the headache phase of migraine attacks, with or without aura.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - film coated tablets - eletriptan hydrobromide 48.485 mg - eletriptan - acute treatment of the headache phase of migraine attacks, with or without aura.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - film coated tablets - eletriptan hydrobromide 96.97 mg - eletriptan - acute treatment of the headache phase of migraine attacks, with or without aura.

Israel - English - Ministry of Health

abbott medical laboratories ltd, israel - omega-3 acid ethyl esters - capsules - omega-3 acid ethyl esters 1000 mg - omega-3-triglycerides - omega-3-triglycerides - post myocardial infarction: adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (e.g. statins, antiplatelet drugs, betablockers, ace inhibitors). hypertriglyceridaemia: endogenous hypertriglyceridaemia as a supplement to diet when dietary measures alone are insufficient to produce an adequate response: - type iv hypertriglyceridaemia. - type iib/iii hypertriglyceridaemia in combination with statin, when control of triglycerides by statins is insufficient.

Israel - English - Ministry of Health

dexcel ltd, israel - isosorbide mononitrate - tablets - isosorbide mononitrate 40 mg - isosorbide mononitrate - isosorbide mononitrate - for the treatment of angina pectoris and prevention of anginal attacks, treatment of congestive heart failure.

Israel - English - Ministry of Health

dexcel ltd, israel - isosorbide mononitrate - tablets - isosorbide mononitrate 20 mg - isosorbide mononitrate - isosorbide mononitrate - for the treatment of angina pectoris and prevention of anginal attacks. treatment of congestive heart failure.

Israel - English - Ministry of Health

unipharm ltd, israel - risedronic acid - tablets - risedronic acid 35 mg - risedronic acid - risedronic acid - treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. treatment of osteoporosis in men at high risk of fracture.

Israel - English - Ministry of Health

cts chemical industries ltd, israel - selegiline hydrochloride - tablets - selegiline hydrochloride 5 mg - selegiline - selegiline - treatment of parkinson's disease or symptomatic parkinsonism.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - film coated tablets - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - film coated tablets - saxagliptin as hydrochloride 2.5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.